Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - FACC, Wolftank-Adisa; Marinomed (20/11/2020)

22.11.2020

FACC: In recognition of its revolutionary autonomous air taxi, aerospace supplier FACC has now been presented with the Gold Innovation Award of the State of Upper Austria. Since November 2018, FACC has been working in this future-oriented field to research and implement complete solutions in order to prepare for a new mobility market with enormous potential. Robert Machtlinger, CEO of FACC AG, is convinced: "With our autonomous air vehicle, we are pursuing a shared vision of making personal mobility in urban agglomerations even more flexible, fast, efficient and safe. Autonomous flying is an additional and completely new answer to congested roads, air pollution and noise exposure in the megacities of this world.” He adds: “In our cooperation with EHang, we are relying on innovative materials, highly efficient lightweight structures, an environmentally friendly electric drive, a high-speed computer and big data. The technology we are employing is truly revolutionary. FACC and EHang complement each other perfectly with respect to their areas of competence.”
FACC: weekly performance: 23.40%

Wolftank-Adisa: Due to the current situation around the Covid-19 pandemic and the currently ongoing uncertainty in connection with the second infection wave and the corresponding lock-down, the Board of Wolftank-Adisa Holding AG, the parent company of an international group of companies focusing on environmental protection services for polluted soil, facilities and water, remediation and monitoring of (large) tank facilities, as well as full-service engineering services for (Hydrogen / LNG) tank facilities, has to reduce the guidance published in the middle of this year. 
Despite a significantly better order intake situation compared to previous years, sales and profit for 2020 will be significantly below the original guidance (sales range of Euro 46 to 56 mn and an EBITDA between Euro 2.6 and 5.6 mn.). At this point, sales of around Euro 35 million and an Ebit of Euro minus two million are expected, but Ebitda is expected to be positive. The currently very strong order backlog – partly due to orders being postponed until next year (2021) – makes the management confident that organic sales will remain at the level of 2019 with even improved profit margins. The Management Board also expects significant positive effects from possible acquisitions.
Wolftank-Adisa Holding AG: weekly performance: 0.00%

Marinomed: Marinomed Biotech AG, a globally operating biopharmaceutical company, announced plans to initiate a Phase IV clinical trial with Carragelose® (iota-carrageenan). The trial will recruit healthcare professionals, who are managing Covid-19 patients, as study population. The primary objective of the trial is to demonstrate that the prophylactic treatment reduces the symptoms of Sars-CoV-2 and other respiratory viral infections when compared to a placebo-treated control group. The randomized double blinded trial is expected to start immediately after the approval of the ethics committee and will enrol 334 individuals. Over the course of 12 weeks, participants will use a Carragelose nasal spray (1.2 mg/ml; 140 µl per puff), marketed under the brand name Coldamaris pro in Austria, three times a day: one dose of the spray into the nostrils plus three doses into the mouth each time. Participants will be screened every week for SARS-CoV-2 and other common respiratory viral infections. Currently, the trials are planned to start at Klinik Favoriten and Klinik Floridsdorf, both based in Vienna, Austria.
Marinomed Biotech: weekly performance: 6.19%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/11/2020)


Partners









latest 21st Austria

21st Austria weekly - FACC, Wolftank-Adisa; Marinomed (20/11/2020)


22.11.2020


FACC: In recognition of its revolutionary autonomous air taxi, aerospace supplier FACC has now been presented with the Gold Innovation Award of the State of Upper Austria. Since November 2018, FACC has been working in this future-oriented field to research and implement complete solutions in order to prepare for a new mobility market with enormous potential. Robert Machtlinger, CEO of FACC AG, is convinced: "With our autonomous air vehicle, we are pursuing a shared vision of making personal mobility in urban agglomerations even more flexible, fast, efficient and safe. Autonomous flying is an additional and completely new answer to congested roads, air pollution and noise exposure in the megacities of this world.” He adds: “In our cooperation with EHang, we are relying on innovative materials, highly efficient lightweight structures, an environmentally friendly electric drive, a high-speed computer and big data. The technology we are employing is truly revolutionary. FACC and EHang complement each other perfectly with respect to their areas of competence.”
FACC: weekly performance: 23.40%

Wolftank-Adisa: Due to the current situation around the Covid-19 pandemic and the currently ongoing uncertainty in connection with the second infection wave and the corresponding lock-down, the Board of Wolftank-Adisa Holding AG, the parent company of an international group of companies focusing on environmental protection services for polluted soil, facilities and water, remediation and monitoring of (large) tank facilities, as well as full-service engineering services for (Hydrogen / LNG) tank facilities, has to reduce the guidance published in the middle of this year. 
Despite a significantly better order intake situation compared to previous years, sales and profit for 2020 will be significantly below the original guidance (sales range of Euro 46 to 56 mn and an EBITDA between Euro 2.6 and 5.6 mn.). At this point, sales of around Euro 35 million and an Ebit of Euro minus two million are expected, but Ebitda is expected to be positive. The currently very strong order backlog – partly due to orders being postponed until next year (2021) – makes the management confident that organic sales will remain at the level of 2019 with even improved profit margins. The Management Board also expects significant positive effects from possible acquisitions.
Wolftank-Adisa Holding AG: weekly performance: 0.00%

Marinomed: Marinomed Biotech AG, a globally operating biopharmaceutical company, announced plans to initiate a Phase IV clinical trial with Carragelose® (iota-carrageenan). The trial will recruit healthcare professionals, who are managing Covid-19 patients, as study population. The primary objective of the trial is to demonstrate that the prophylactic treatment reduces the symptoms of Sars-CoV-2 and other respiratory viral infections when compared to a placebo-treated control group. The randomized double blinded trial is expected to start immediately after the approval of the ethics committee and will enrol 334 individuals. Over the course of 12 weeks, participants will use a Carragelose nasal spray (1.2 mg/ml; 140 µl per puff), marketed under the brand name Coldamaris pro in Austria, three times a day: one dose of the spray into the nostrils plus three doses into the mouth each time. Participants will be screened every week for SARS-CoV-2 and other common respiratory viral infections. Currently, the trials are planned to start at Klinik Favoriten and Klinik Floridsdorf, both based in Vienna, Austria.
Marinomed Biotech: weekly performance: 6.19%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/11/2020)




 

Bildnachweis

Aktien auf dem Radar:Semperit, Marinomed Biotech, FACC, Warimpex, Mayr-Melnhof, Agrana, DO&CO, ATX Prime, Immofinanz, Österreichische Post, SBO, Polytec Group, ATX, UBM, CA Immo, Erste Group, RBI, Athos Immobilien, Cleen Energy, Porr, SW Umwelttechnik.


Random Partner

Rosenbauer
Rosenbauer ist weltweit der führende Hersteller für Feuerwehrtechnik im abwehrenden Brand- und Katastrophenschutz. Als Vollsortimenter bietet Rosenbauer der Feuerwehr kommunale Löschfahrzeuge, Drehleitern, Hubrettungsbühnen, Flughafenfahrzeuge, Industriefahrzeuge, Sonderfahrzeuge, Löschsysteme, Feuerwehrausrüstung, stationäre Löschanlagen und im Bereich Telematik Lösungen für Fahrzeugmanagement und Einsatzmanagement.

>> Besuchen Sie 58 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten